<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146016</url>
  </required_header>
  <id_info>
    <org_study_id>CIRA-study</org_study_id>
    <nct_id>NCT00146016</nct_id>
  </id_info>
  <brief_title>Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients</brief_title>
  <official_title>Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      * Adding Amantadine to standard anti-viral treatment can improve sustained response rates in
      patients with chronic hepatitis C
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CIRA-study is a double blind, placebo controlled, randomised, multicentre study in
      previously untreated patients suffering from chronic hepatitis C comparing double therapy,
      consisting of (PEG-)interferon alpha 2b ((PEG)Intron-A®) and ribavirin (Rebetol®), with
      triple therapy, consisting of (PEG-)interferon alpha 2b, ribavirin and amantadine, for 52
      weeks. Follow-up is completed at week 104. 150 Subjects per treatment group will be included.
      Patients will be stratified before randomisation according to genotype (1 versus non-1).
      Viral load will not be a discriminating factor.

      The aim is to investigate the efficacy of the adjunct amantadine to the currently used
      combination therapy with interferon alpha and ribavirin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at end of treatment and end of follow-up (sustained response rate)</measure>
  </primary_outcome>
  <enrollment>390</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-HCV positivity &gt;6 months

          -  ALT and/or AST elevation on at least once in the previous 6 months

          -  Positive HCV-RNA

          -  Liver biopsy within one year before the start of therapy in non- cirrhosis. In the
             case of known cirrhosis, liver biopsy is not necessary

          -  Intention to be treated and participate treatment

          -  Obtained written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnancy or intention to get pregnant within the 12 months period of treatment and up
             to 6 months after discontinuation of therapy, no adequate contraception, lactation

          -  Men not practicing or willing to practice acceptable methods of contraception during
             the treatment period and up to 6 months after discontinuation of therapy

          -  Life expectancy &lt; 1 year

          -  Child Pugh B or C (Appendix III)

          -  Creatinine &gt; 150 μmol/L or &gt; 1.70 mg/dl

          -  Haemoglobulin &lt; 6.5 mmol/l or &lt; 10.5 g/dl

          -  White blood cell count &lt; 2,5 x 109/L, neutrophil &lt; 1,5 x 109/L

          -  Platelet count &lt; 70 x 109/L

          -  HIV positivity

          -  Chemotherapy, systematical antiviral treatment during the 6 months prior to study
             entry

          -  Other serious disease (e.g. malignancy, uncontrolled myocardial disease or severe
             arrhythmias)

          -  Active uncontrolled psychiatric disorders and suicidal leanings

          -  Patients with a history of uncontrolled seizure or other significant CNS dysfunction

          -  Any condition which in the opinion of the (co-)investigator might interfere with the
             evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel v. Erpecum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht, dept. Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melvin Samsom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht, dept gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology. 2003 Jun;37(6):1359-67.</citation>
    <PMID>12774015</PMID>
  </reference>
  <reference>
    <citation>Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology. 2000 Sep;32(3):630-4.</citation>
    <PMID>10960460</PMID>
  </reference>
  <reference>
    <citation>Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci. 2005 May;50(5):970-5.</citation>
    <PMID>15906777</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 1, 2005</last_update_submitted>
  <last_update_submitted_qc>September 1, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2005</last_update_posted>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Amantadine</keyword>
  <keyword>Triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

